Zeltia SA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Zeltia SA’s Subsidiary, Noscira SA, To Propose Dissolution
Zeltia SA announced that its subsidiary, Noscira SA, has decided to hold the Extraordinary Shareholders’ Meeting on December 18, 2012 or December 19, 2012 and propose a dissolution of Noscira SA due to the deterioration of the company’s investment.
Latest Developments for Zeltia SA
- Zeltia SA's Subsidiary Noscira SA To Be Dissolved
- Zeltia SA’s Pharma Mar Receives 14 New Marketing Authorizations For Yondelis In 10 Countries-Reuters
- Zeltia SA Announces Negative Results From Phase II Trial Of Alzheimer Treatment-Reuters
- Zeltia SA Announces Results From Phase II Trial Of Noscira's Alzheimer's Treatment-Reuters
Latest Key Developments in Biotechnology
- BioSpecifics Technologies Corp announces FDA approval of XIAFLEX for treatment of peyronie's disease
- Xencor Inc announces closing of initial public offering
- Genmab reaches milestone from Janssen and raises FY 2013 financial guidance
- Genmab says milestone from Lundbeck puts revenue at top end of FY 2013 outlook range
- Share this
- Digg this